{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:43Z","timestamp":1781927563806,"version":"3.54.5"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7661-26","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:10:20Z","timestamp":1781734220000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Dual Treatment of Crohn's Disease and Atopic Dermatitis with Upadacitinib: Two Case Reports"],"prefix":"10.2169","author":[{"given":"Kentaro","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ibuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chen ML, Sundrud MS. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflamm Bowel Dis 22: 1157-1167, 2016.","DOI":"10.1097\/MIB.0000000000000714"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2: 110, 2011.","DOI":"10.4172\/2155-9899.1000110"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123: 1244-1252.e2, 2009.","DOI":"10.1016\/j.jaci.2009.03.041"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol 13: 1068260, 2022.","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. The future of Janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis 11: 885-893, 2017.","DOI":"10.1093\/ecco-jcc\/jjx003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 15: 23, 2017.","DOI":"10.1186\/s12964-017-0177-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66: 311-328, 2015.","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 397: 2151-2168, 2021.","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med 388: 1966-1980, 2023.","DOI":"10.1056\/NEJMoa2212728"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Novielli D, Foti C, Principi M, et al. Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: a case report. J Eur Acad Dermatol Venereol 38: e8-e10, 2024.","DOI":"10.1111\/jdv.19377"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bueno-Filho R, Lorenzini D, Parra RS. Efficacy of upadacitinib in the management of atopic dermatitis, Crohn's disease, and hidradenitis suppurativa: one treatment, multiple indications. An Bras Dermatol 100: 583-586, 2025.","DOI":"10.1016\/j.abd.2024.10.007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sugino Y, Ban H, Yoshino Y, Takaki Y, Furuse A. Pediatric case of Crohn disease, immunoglobulin A nephropathy, and atopic dermatitis. Pediatrics 155: e2024068803, 2025.","DOI":"10.1542\/peds.2024-068803"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mortato E, Rao LM, Aloi M, et al. Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn's disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient. Dermatol Rep 2026.","DOI":"10.4081\/dr.2026.10165"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Levine J, Sharma D, Morsia S, Ungar B. Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil. J Dermatolog Treat 36: 2528704, 2025.","DOI":"10.1080\/09546634.2025.2528704"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology 161: 1118-1132, 2021.","DOI":"10.1053\/j.gastro.2021.07.042"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lee H, Lee JH, Koh SJ, Park H. Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: a systematic review and meta-analysis. J Am Acad Dermatol 83: 1385-1394, 2020.","DOI":"10.1016\/j.jaad.2020.05.130"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chiesa Fuxench ZC, Wan J, Wang S, et al. Risk of inflammatory bowel disease in patients with atopic dermatitis. JAMA Dermatol 159: 1085-1092, 2023.","DOI":"10.1001\/jamadermatol.2023.2875"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zysk W, Mesjasz A, Trzeciak M, Horvath A, Plata-Nazar K. Gastrointestinal comorbidities associated with atopic dermatitis-a narrative review. Int J Mol Sci 25: 1194, 2024.","DOI":"10.3390\/ijms25021194"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. De Salvo C, Buela KA, Creyns B, et al. NOD2 drives early IL-33-dependent expansion of group 2 innate lymphoid cells during Crohn's disease-like ileitis. J Clin Invest 131: e140624, 2021.","DOI":"10.1172\/JCI140624"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 160: 2496-2508, 2021.","DOI":"10.1053\/j.gastro.2021.04.022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 90: e43-e56, 2024.","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Elosua Gonzalez A, Zabalza L, Vicu\u00f1a M, et al. Real-world effectiveness of upadacitinib induction therapy in Crohn's disease, with a focus on patients with concomitant IMIDs. J Crohns Colitis 19 (Suppl 1): i1838, 2025.","DOI":"10.1093\/ecco-jcc\/jjae190.1164"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Konzett V, Smolen JS, Nash P, et al. Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement. Ann Rheum Dis 84: 697-715, 2025.","DOI":"10.1016\/j.ard.2025.01.024"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7661-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:38:01Z","timestamp":1781926681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7661-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7661-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7661-26"}}